Intelligent delivery of autophagy-targeting chimeric peptides by engineered exosomes for the degradation of a-synuclein

Apr 6, 2026Acta biomaterialia

Smart delivery of engineered cell messengers carrying peptides to break down a-synuclein

AI simplified

Longevity & Aging on OpenScience ↗PubMed ↗DOI ↗

Abstract

The engineered exosomes, NGFLG-P1, effectively cross the blood-brain barrier and target diseased substantia nigra neurons.

NGFLG-P1 exosomes are designed with specific peptides to enhance their ability to reach and affect neurons in the substantia nigra, which are primarily impacted in Parkinson's disease.
After entering the cells, NGFLG-P1 releases a peptide that degrades aggregated α-synuclein, a protein implicated in the pathology of Parkinson's disease.
The ability of NGFLG-P1 exosomes to degrade α-synuclein aggregates was demonstrated in a mouse model of Parkinson's disease induced by MPTP.
This approach addresses challenges related to blood-brain barrier permeability and targeted delivery of therapeutic agents to affected neurons.

AI simplified

Targeted degradation of the aggregated α-synuclein holds tremendous potential for treating Parkinson's disease (PD). However, most of the developed aggregated α-synuclein-specific degraders, e.g., autophagy-targeting chimeric peptides, are limited by the blood-brain barrier (BBB), substantia nigra (SN) neuron targetability, and intracytoplasmic release. To overcome these obstacles, we constructed an engineered exosome (EXO) equipped with surficial glucose-regulated protein 94 (GRP94)-targeting peptide N, luminal α-synuclein-degrading peptide P1, and cathepsin-B-cleavable GFLG as the linker between the exosome skeleton protein and P1, termed NGFLG-P1. We verified that the NGFLG-P1 exosomes could cross the BBB and target diseased SN neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride (MPTP)-induced PD model mice. Following fusion with endosomes, the exposed P1 was released into the cytoplasm by cytoplasmic cathepsin B-mediated GFLG cleavage to degrade α-synuclein. Collectively, the NGFLG-P1 exosomes exhibit a significant degradation effect on α-synuclein aggregates, providing a proof-of-concept platform for treating PD. STATEMENT OF SIGNIFICANCE: Targeted degradation of α-synuclein aggregates holds tremendous potential for the etiological treatment of Parkinson's disease (PD). However, most of current α-synuclein-specific degraders are stuck with low blood-brain barrier permeability, poor targetability for diseased cells, and uncontrolled release. Notably, α-synuclein predominantly affects neurons in the substantia nigra (SN) region rather than the whole brain. To overcome these obstacles, we constructed an engineered exosome, termed NGFLG-P1, to specially deliver and release autophagy-targeting chimeric peptide to degrade α-synuclein in the diseased SN neurons through the autophagy-lysosomal pathway. The engineered exosomes exhibit the great potential in targeting diseased SN neurons and degrading α-synuclein aggregates, providing a proof-of-concept therapeutic platform for treating PD. EXO EXO EXO EXO

Full Text

Full text is available at the source.

View full text (XML) ↗View full text ↗

Intelligent delivery of autophagy-targeting chimeric peptides by engineered exosomes for the degradation of a-synuclein

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the longevity & aging brief